Clinical trials: Niraparib
Head and Neck Cancer
Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC
The purpose of this study is to determine the best overall response of the combination of dostarlimab and niraparib in patients with recurrent and/or metastatic HNSCC patients.
- Trial name
- NCT04313504
- Testing
- Niraparib, Dostarlimab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Trisha Wise-Draper
Mesothelioma, Uveal Melanoma
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
This open-label, non-randomized study will investigate the use of niraparib in patients with tumors known to have mutations in BAP1 and other select DNA damage response pathway genes.
- Conditions
- Mesothelioma, Uveal Melanoma, Renal Cell Carcinoma, Cholangiocarcinoma
- Trial name
- NCT03207347
- Testing
- Niraparib
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- University of Florida
Biliary Tract Neoplasms
Personalized Medicine for Advanced Biliary Cancer Patients
The object of this trial is to evaluate whether the introduction of a targeted therapy after 4 cycles of the current standard-of-care treatment for advanced biliary cancer is superior to continuing with the standard treatment.
- Trial name
- SAFIR-ABC10 (NCT05615818)
- Testing
- Futibatinib, Ivosidenib, Zanidatamab
- Where
- 69 sites in Belgium, France and 1 more
- Volunteers
- 800 people
- Sponsor
- UNICANCER
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
This is a phase I-II trial to find the safety and activity of adding a new drug (neraparib) to the usual treatment (radiation combined with male hormone deprivation therapy) in lowering the chance of prostate cancer growing or…
- Conditions
- Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04037254
- Testing
- Gonadotrophin Releasing Hormone, Intensity-Modulated Radiation Therapy, Niraparib
- Where
- 95 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- NRG Oncology
Cancer
Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to PARP Inhibitors (MyeloRIB)
Although PARP inhibitors (PARPi) have proved effective in treating many cancers, few patients receiving PARPi may experience rare but life-threatening adverse events such as myelodysplastic syndrome (MDS) and/or acute myeloid…
- Trial name
- NCT04326023
- Testing
- PARP Inhibitors
- Where
- France
- Volunteers
- 178 people
- Sponsor
- University Hospital, Caen
Advanced Solid Tumor
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
This study is to assess the safety and tolerability, obtain the recommended phase 2 dose(RP2D)/or Maximum Tolerated Dose (MTD) for LM-2417 as a single agent or in combination with other anti-tumour agents in subjects with…
- Trial name
- NCT06682780
- Testing
- LM-2417, Docetaxel, Toripalimab/Tirelizumab
- Where
- China
- Volunteers
- 320 people
- Sponsor
- LaNova Medicines Limited
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
In April 2017, Tesaro, Inc. opened an expanded access program (EAP) to make niraparib, an investigational poly (ADP-ribose) polymerase (PARP) inhibitor, available to eligible women with recurrent epithelial ovarian, fallopian…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT04546373
- Testing
- Niraparib
- Where
- 57 sites in Spain
- Volunteers
- 316 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Ovarian Cancer
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
This is a prospective, interventional, single-arm, open-label, phase II study to evaluate the safety and efficacy of niraparib monotherapy as neoadjuvant therapy in patients with advanced ovarian cancer, primary peritoneal…
- Trial name
- NCT04507841
- Testing
- Niraparib
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Tongji Hospital
Breast Neoplasms, Breast Cancer
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early…
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma
- Trial name
- I-SPY (NCT01042379)
- Testing
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin
- Where
- 42 sites in United States
- Volunteers
- 5,000 people
- Sponsor
- QuantumLeap Healthcare Collaborative
Advanced Solid Tumor, Breast Cancer
Study of M4344 in Combination With Niraparib
Study will include 3 parts. Aim of Part 1 of this study is to establish the maximum tolerated dose (MTD) and recommended dose for expansion (RDE) for M4344 (is an Ataxia Telangiectasia Mutated and Rad3-related [ATR] inhibitors)…
- Trial name
- NCT04655183
- Testing
- Niraparib, M4344
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Epithelial Ovarian Cancer, Ovarian Cancer
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
This study is the phase IV, open-label, clinical trial to determine the efficacy of niraparib maintenance therapy in BRCA1/2 wild-type, advanced-stage, low-risk, primary ovarian cancer patients.
- Conditions
- Epithelial Ovarian Cancer, Ovarian Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV
- Trial name
- POLO (NCT05187208)
- Testing
- Niraparib
- Volunteers
- 102 people
- Sponsor
- Seoul National University Hospital
Nasopharyngeal Carcinoma
Niraparib And Sintilimab In Recurrent/Metastatic Nasopharyngeal Carcinoma
this study is aimed to evaluate the efficacy and safety of the combination of Niraparib and Sintilimab in the treatment of recurrent/metastatic nasopharyngeal carcinoma
- Trial name
- NCT05162872
- Testing
- Niraparib，Sintilimab
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Sun Yat-sen University
Ovarian Cancer Recurrent
Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer
The purpose of this study is to find out if a new drug, M4344, is safe and has beneficial effects when given in combination with the PARP inhibitor, Niraparib, in women with recurrent ovarian cancer that has progressed while on a…
- Trial name
- PARP (NCT04149145)
- Testing
- M4344+Niraparib
- Sponsor
- University of Alabama at Birmingham
Ovarian Neoplasms, Fallopian Tube Neoplasms
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
Niraparib is an oral, potent and highly selective PARP1/2 inhibitor. It can be used as a single drug in HRD positive ovarian cancer patients for multi-line therapy.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Endocrine Gland Neoplasms, Neoplasms by Site
- Trial name
- AVANIRA3 (NCT04556071)
- Testing
- Niraparib, Bevacizumab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Xiaoxiang Chen
Triple Negative Breast Cancer, Residual Disease
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
- Trial name
- UNITY (NCT03945721)
- Testing
- Niraparib, Radiation Therapy
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Massachusetts General Hospital
HRD, Cholangiocarcinoma
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Phase II, single arm trial, evaluating molecularly selected, immune-based combination therapy in maintenance treatments for advanced cholangiocarcinoma, selecting patients on the homologous recombination deficient (HRD) signature.
- Conditions
- HRD, Cholangiocarcinoma, Metastatic Cancer
- Trial name
- NCT04895046
- Testing
- Niraparib, Dostarlimab
- Sponsor
- Walid Shaib, MD
Mesothelioma, Malignant
Niraparib Efficacy in Patient With Unresectable Mesothelioma
Multicentre, 2 arm, open-label UK randomised phase II trial to determine the efficacy of niraparib versus active symptom control (ASC) in patients who have relapsed after previously receiving platinum based systemic therapy.
- Trial name
- NERO (NCT05455424)
- Testing
- Niraparib Oral Product, Active Symptom Control
- Where
- 11 sites in United Kingdom
- Volunteers
- 88 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Prostate Cancer
A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer
The purpose of this study is to establish the maximum tolerable dose of niraparib when combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone (the phase 1 portion of the study) and…
- Trial name
- ASCLEPIuS (NCT04194554)
- Testing
- Niraparib, Leuprolide, Abiraterone Acetate
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- University of Michigan Rogel Cancer Center
Solid Tumor
A MolEcularly Guided Anti-Cancer Drug Off-Label Trial
This is a prospective, open-label, non-randomized combined basket- and umbrella trial divided in two parts; a limited feasibility-oriented part 1 including 154 patients and 3 treatment cohorts and part 2 that will include an…
- Trial name
- MEGALiT (NCT04185831)
- Testing
- Atezolizumab, Everolimus, Cobimetinib
- Where
- 3 sites in Sweden
- Volunteers
- 167 people
- Sponsor
- Uppsala University Hospital
Ovarian Neoplasms, Breast Neoplasms
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
This is a global extension study to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment in participants who are currently receiving treatment with niraparib within…
- Trial name
- NCT04641247
- Testing
- Niraparib
- Where
- 25 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- GlaxoSmithKline